Special Issue

Application of Magnetic Resonance Imaging (MRI) in Diagnosis and Treatment of Mental Diseases

Message from the Guest Editors

This Special Issue will focus on the recent advances in the use of magnetic resonance imaging (MRI) for the diagnosis and pharmacological treatment of mental diseases. In recent years, the field has made extraordinary progress in to identify imaging biomarkers as potential tools to improve the prevention, diagnosis and pharmacological treatment of mental diseases. Such as major depressive disorders using brain volumetric magnetic resonance imaging (MRI), functional MRI (resting-state and affective tasks), diffusion tensor imaging, magnetic resonance spectroscopy, near-infrared spectroscopy, and molecular imaging (i.e., positron emission tomography and single photon emission computed tomography). In this Special Issue, we welcome preclinical and clinical studies that underscore the application of Magnetic Resonance Imaging (MRI) in the diagnosis and pharmacological treatment of mental diseases using potential biomarkers to provide a better understanding of the pathophysiology and effective ways to personalize treatment in mental diseases as well as provide new insights into pharmacology in the psychiatric field.

Guest Editors

Prof. Dr. Deborah A. Yurgelun-Todd

Dr. Douglas Kondo

Dr. Nicolas A Nunez

Dr. Perry Franklin Renshaw

Deadline for manuscript submissions

closed (5 August 2024)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/196364

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/pharmaceuticals





Pharmaceutica

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals*.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

